Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12850779 | 0.97 | HTR2B (0.40) | HTR2BGPR35MAPTTSHRCHEK2 | |
| SCHEMBL26121507 | 0.97 | HTR2B (0.40) | HTR2BGPR35MAPTTSHRCHEK2 | |
| SCHEMBL21515798 | 0.97 | HTR2B (0.40) | HTR2BGPR35MAPTTSHRCHEK2 | |
| SCHEMBL21515889 | 0.97 | HTR2B (0.40) | HTR2BGPR35MAPTTSHRCHEK2 | |
| SCHEMBL12850797 | 0.97 | HTR2B (0.40) | HTR2BGPR35MAPTTSHRCHEK2 | |
| SCHEMBL20180855 | 0.93 | HTR2B (0.41) | HTR2BGPR35MAPTTSHRPPARD | |
| SCHEMBL18499306 | 0.91 | HTR2B (0.43) | HTR2BMAPTTSHRCHEK2HSP90AA1 | |
| SCHEMBL18189564 | 0.90 | MAPT (0.44) | HTR2BGPR35MAPTTSHR | |
| SCHEMBL18189563 | 0.90 | MAPT (0.44) | HTR2BGPR35MAPTTSHR | |
| SCHEMBL18499307 | 0.88 | HTR2B (0.40) | HTR2BMAPTTSHRCHEK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994535-B2 | Desferrithiocin polyether analogues | UNIVERSITY OF FLORIDA FOUNDATION, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994535-B2 | Desferrithiocin polyether analogues | UNIVERSITY OF FLORIDA FOUNDATION, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170217912-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170217912-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| EP-3190106-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | University of Florida Research Foundation, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9567309-B2 | Desferrithiocin polyether analogues | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567309-B2 | Desferrithiocin polyether analogues | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150336911-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336911-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-11-26 | — | — | US | disclosed |
| US-9096553-B2 | Desferrithiocin polyether analogues | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140235680-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235680-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8722899-B2 | Desferrithiocin polyether analogues | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722899-B2 | Desferrithiocin polyether analogues | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130030028-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030028-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8278458-B2 | Desferrithiocin polyether analogues | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278458-B2 | Desferrithiocin polyether analogues | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20080214630-A1 | Oral bioavailability; minimal toxicity; low concentration in the kidneys after administration; reduce oxidative stress; (S)-4,5-Dihydro-2-[2-hydroxy-4-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic acid; condition responsive to chelation or sequestration of a trivalent metal | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214630-A1 | Oral bioavailability; minimal toxicity; low concentration in the kidneys after administration; reduce oxidative stress; (S)-4,5-Dihydro-2-[2-hydroxy-4-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic acid; condition responsive to chelation or sequestration of a trivalent metal | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030028-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | SLC40A1, DNAJC10, FTH1 | HTR2B 4638/4885GPR35 4385/4885MAPT 1849/4885 |
| US-20150336911-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | SLC40A1, DNAJC10, FTH1 | HTR2B 4638/4885GPR35 4385/4885MAPT 1849/4885 |
| US-20170217912-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | SLC40A1, DNAJC10, FTH1 | HTR2B 4638/4885GPR35 4385/4885MAPT 1849/4885 |
| US-20080214630-A1 | Oral bioavailability; minimal toxicity; low concentration in the kidneys after administration; reduce oxidative stress; (S)-4,5-Dihydro-2-[2-hydroxy-4-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic acid; condition responsive to chelation or sequestration of a trivalent metal | SLC7A1, SLC19A1, SLC10A6 | HTR2B 3212/4885GPR35 2803/4885MAPT 2950/4885 |
| US-20140235680-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES | SLC40A1, DNAJC10, FTH1 | HTR2B 4638/4885GPR35 4385/4885MAPT 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.